| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The continuing spread of drug-resistant malaria emphasizes the need for new antimalarial drugs. Atovaquone is a broad-spectrum antiprotozoal drug with a novel mechanism of action, via inhibition of parasite mitochondrial electron transport, and a favorable safety profile. Early studies with atovaquone alone for treatment of malaria demonstrated good initial control of parasitemia but an unacceptable rate of recrudescent parasitemia. Parasites isolated during recrudescence after treatment with atovaquone alone were resistant to atovaquone in vitro. The combination of atovaquone and proguanil is synergistic in vitro, and clinical studies demonstrated enhanced efficacy of the combination compared to either drug alone for treatment of malaria. Malarone, a fixed-dose combination of 250 mg of atovaquone and 100 mg of proguanil hydrochloride, is available in many countries for treatment of acute, uncomplicated malaria caused by Plasmodium falciparum. At the recommended dose (in adults, four tablets once a day for three days), the overall cure rate was > 98% in more than 500 patients with falciparum malaria. In four randomized, controlled clinical trials, treatment with atovaquone and proguanil hydrochloride was significantly more effective than mefloquine (Thailand), amodiaquine (Gabon), chloroquine (Peru and the Philippines) or chloroquine plus pyrimethamine/sulfadoxine (Philippines). In clinical trials where the comparator drug was highly effective, treatment with atovaquone and proguanil hydrochloride was equally effective. Parasites isolated during recrudescence after treatment with the combination of atovaquone and proguanil were not resistant to atovaquone in vitro. The most commonly reported adverse events in clinical trials (abdominal pain, anorexia, nausea, vomiting, diarrhea and coughing) occurred with similar frequency in patients treated with a comparator drug. Malarone is a safe and effective new agent for treatment of malaria.
This article has been cited by other articles:
|
|
 |
|
  A. K. BOGGILD, M. E. PARISE, L. S. LEWIS, and K. C. KAIN ATOVAQUONE-PROGUANIL: REPORT FROM THE CDC EXPERT MEETING ON MALARIA CHEMOPROPHYLAXIS (II) Am J Trop Med Hyg, February 1, 2007; 76(2): 208 - 223. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Daily Antimalarial drug therapy: the role of parasite biology and drug resistance. J. Clin. Pharmacol., December 1, 2006; 46(12): 1487 - 1497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Musset, B. Pradines, D. Parzy, R. Durand, P. Bigot, and J. Le Bras Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers J. Antimicrob. Chemother., January 1, 2006; 57(1): 110 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ranque, B. Marchou, D. Malvy, E. Adehossi, R. Laganier, H. Tissot-Dupont, A. Lotte, S. Dydymsky, J. Durant, J.-P. Stahl, et al. Treatment of imported malaria in adults: a multicentre study in France QJM, October 1, 2005; 98(10): 737 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. W. Mather, E. Darrouzet, M. Valkova-Valchanova, J. W. Cooley, M. T. McIntosh, F. Daldal, and A. B. Vaidya Uncovering the Molecular Mode of Action of the Antimalarial Drug Atovaquone Using a Bacterial System J. Biol. Chem., July 22, 2005; 280(29): 27458 - 27465. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. BLOSSOM, C. H. KING, and K. B. ARMITAGE OCCULT PLASMODIUM VIVAX INFECTION DIAGNOSED BY A POLYMERASE CHAIN REACTION-BASED DETECTION SYSTEM: A CASE REPORT Am J Trop Med Hyg, July 1, 2005; 73(1): 188 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Baird Effectiveness of Antimalarial Drugs N. Engl. J. Med., April 14, 2005; 352(15): 1565 - 1577. [Full Text] [PDF]
|
|
|
|
 |
|
 Q. L. Fivelman, I. S. Adagu, and D. C. Warhurst Modified Fixed-Ratio Isobologram Method for Studying In Vitro Interactions between Atovaquone and Proguanil or Dihydroartemisinin against Drug-Resistant Strains of Plasmodium falciparum Antimicrob. Agents Chemother., November 1, 2004; 48(11): 4097 - 4102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. K. BASCO MOLECULAR EPIDEMIOLOGY OF MALARIA IN CAMEROON. XVII. BASELINE MONITORING OF ATOVAQUONE-RESISTANT PLASMODIUM FALCIPARUM BY IN VITRO DRUG ASSAYS AND CYTOCHROME B GENE SEQUENCE ANALYSIS Am J Trop Med Hyg, August 1, 2003; 69(2): 179 - 183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Farnert, J. Lindberg, P. Gil, G. Swedberg, Y. Berqvist, M. M Thapar, N. Lindegardh, S. Berezcky, and A Bjorkman Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports BMJ, March 22, 2003; 326(7390): 628 - 629. [Full Text] [PDF]
|
|
|
|
|
|
J. Wiesner, D. Henschker, D. B. Hutchinson, E. Beck, and H. Jomaa In Vitro and In Vivo Synergy of Fosmidomycin, a Novel Antimalarial Drug, with Clindamycin Antimicrob. Agents Chemother., September 1, 2002; 46(9): 2889 - 2894. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Baggish and D. R. Hill Antiparasitic Agent Atovaquone Antimicrob. Agents Chemother., May 1, 2002; 46(5): 1163 - 1173. [Full Text] [PDF]
|
|
|
|
|
|
R. Durand, J. Eslahpazire, S. Jafari, J.-F. Delabre, A. Marmorat-Khuong, J.-P. di Piazza, and J. Le Bras Use of Molecular Beacons To Detect an Antifolate Resistance-Associated Mutation in Plasmodium falciparum Antimicrob. Agents Chemother., December 1, 2000; 44(12): 3461 - 3464. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
